BACTERICIDAL ACTIVITY OF CEFODIZIME ON ENTEROBACTERIACEAE IN AN IN-VITRO MODEL SIMULATING PLASMA PHARMACOKINETICS IN HUMANS

An in-vitro dialysis model was employed to assess the feasibility of o nce-daily dosing of cefodizime in the treatment of infections caused b y various Enterobacteriaceae: Escherichia coil, Klebsiella pneumoniae, Morganella morganii, Serratia marcescens, Providencia stuartii and En terobacter cloacae. This model simulated the concentrations of cefodiz ime detected in human blood after an intravenous (iv) bolus injection of 1 g or 2 g of the antibiotic. Validation of the model was undertake n to confirm its utility. Based on the data obtained with this model, once-daily dosing with 1 g cefodizime (iv) should be effective against infections due to the commonest Gram-negative bacteria (E. coli, K. p neumoniae, M. morganii). For infections caused by Enterobacteriaceae s trains that produce large quantities of Class beta-lactamases, twice-d aily (P. stuartii or S. marcescens) or four times daily (E. cloacae) a dministration of 1 g cefodizime may be required.